(+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, L-DTTA salt | 357399-44-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, L-DTTA salt
• 英文别名: (2R,3R)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid;(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol
• CAS: 357399-44-1
• 化学式: C₁₃H₁₈ClNO₂*C₂₀H₁₈O₈
• 分子量: 642.103
• InChiKey: BDISRUFSVHSHHF-GXYSLXRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  169
• 氢给体数：
  4
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  二对甲苯酰基-L-酒石酸 、 (R,R)-羟基安非他酮 以 乙酸乙酯 为溶剂， 反应 18.0h， 以70%的产率得到(+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, L-DTTA salt
  参考文献：
  名称：

  [EN] RESOLUTION PROCESS FOR PREPARING (+)-(2S,3S)-2-(3-CHLOROPHENYL)-3,3,3-TRIMETHYL-2-MORPHOLINOL
  [FR] PROCEDE DE RESOLUTION POUR LA PREPARATION DE (+)-(2S,3S)-2-(3- CHLOROPHENYL)-3,5,5-TRIMETHYL-2-MORPHOLINOL

  摘要：

  揭示了一种通过动力学拆分制备(+)-(2S,3S)-2-(3-氯苯基)-3,5,5-三甲基-2-吗啉醇及其药用可接受盐，如(+)-(2S,3S)-2-(3-氯苯基)-3,5,5-三甲基-2-吗啉醇盐酸盐的方法。

  公开号：

  WO2005040141A1

文献信息

• Bupropion metabolites and methods of their synthesis and use
  申请人：SEPRACOR INC.

  公开号：US20020052341A1

  公开（公告）日：2002-05-02

  Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.

  本文披露了利用伯泊隆代谢物治疗神经元单胺重摄取抑制所改善的疾病的方法和组合物。这些疾病包括但不限于性功能障碍、情感障碍、脑功能障碍、吸烟和失禁。本文还披露了制备光学纯伯泊隆代谢物的方法。
• Intermediates of bupropion metabolites synthesis
  申请人：Fang Qun Kevin

  公开号：US20060058300A1

  公开（公告）日：2006-03-16

  Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.

  本文公开了利用伯泊隆代谢产物治疗通过抑制神经元单胺再摄取改善的疾病的方法和组合物。这些疾病包括但不限于性功能障碍，情感障碍，脑功能障碍，吸烟和失禁。本文还公开了制备光学纯伯泊隆代谢产物的方法。
• Bupropion Metabolites and Methods of Their Synthesis and Use
  申请人：FANG Kevin Qun

  公开号：US20100125070A1

  公开（公告）日：2010-05-20

  Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.

  本文披露了利用伯泊隆代谢产物治疗通过抑制神经元单胺再摄取得到改善的疾病的方法和组合物。这些疾病包括但不限于性功能障碍、情感障碍、脑功能障碍、吸烟和失禁。本文还披露了制备光学纯伯泊隆代谢产物的方法。
• Bupropion Metabolites and Methods of their Synthesis and Use
  申请人：SEPRACOR, INC.

  公开号：EP1602369A2

  公开（公告）日：2005-12-07

  Methods and compositions are disclosed which utilize metabolites of bupropion for trearing disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.

  本研究公开了利用安非他酮代谢物治疗因抑制神经元单胺再摄取而恶化的疾病的方法和组合物。这些疾病包括但不限于性功能障碍、情感障碍、脑功能障碍、吸烟和大小便失禁。还公开了制造光学纯安非他明代谢物的方法。
• BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE
  申请人：SEPRACOR, INC.

  公开号：EP1259243B1

  公开（公告）日：2006-06-28